12 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.
Philipps University Marburg
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Johnson & Johnson Pharmaceutical
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
Ambrilia Biopharma
Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
Pharmacor
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureas.
Procyon Biopharma
Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacer.
Pharmacor
1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitors.
Pharmacor
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
Dupont Pharmaceuticals
An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Academy Of Sciences Of The Czech Republic
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
University Of Florida College Of Medicine
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
University Of Pennsylvania